Piero Dalerba, MD, is a medical oncologist and an assistant professor of medicine, pathology and cell biology at Columbia University’s Herbert Irving Comprehensive Cancer Center in New York City. Dr. Dalerba directs a research laboratory whose main interest is to use modern “single-cell genomics” technologies to identify novel biomarkers of “cancer stem cells”, and to explore their potential as: 1) novel predictive biomarkers to improve treatment algorithms for cancer patients; 2) novel pharmacological targets to develop innovative anti-tumor treatments. Dr. Dalerba has a long-standing expertise in the biology and medical treatment of human colon cancer. His research contributions include: a) the observation that, in human colon carcinomas, the capacity for unlimited proliferation, also known as “cellular immortality”, is often not a constitutive trait of all malignant cells (Dalerba et al., Cancer Research, 65:2321-2329, 2005); b) the discovery of CD44 and CD166/ALCAM as robust surface markers for the ex vivo isolation of human colon “cancer stem cells” (Dalerba et al., PNAS, 100:3983-3988, 2007); c) the first use of “single-cell genomics” to dissect the cell composition of human colorectal malignancies, discover novel subtypes of human colon epithelial cells and provide formal proof of multi-lineage differentiation as an epigenetic source of intra-tumor cell heterogeneity (Dalerba et al., Nature Biotechnology, 29:1120-1127, 2011). Dr. Dalerba is the recipient of a 2016 Damon Runyon-Rachleff Innovator Award and the principal investigator on a 2012 career-development Young Investigator Award (YIA) from the National Comprehensive Cancer Network (NCCN), which supported a research project entitled: Evaluation of CDX2 as a novel predictive biomarker to guide therapeutic algorithm design in colon cancer.